Related references
Note: Only part of the references are listed.Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Sheng Zhou et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Tracey G. Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity
Gary A. Piazza et al.
DRUG DISCOVERY TODAY (2020)
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death
Joseph Longo et al.
MOLECULAR ONCOLOGY (2020)
Use of terbinafine and risk of death in patients with prostate cancer: A population-based cohort study
Jianguang Ji et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten et al.
IMMUNITY (2019)
Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells
Marcos P. Thome et al.
EXPERIMENTAL CELL RESEARCH (2019)
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
George S. Baillie et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways
Bing Huang et al.
CELL (2019)
Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation
Marcos P. Thome et al.
ANTIVIRAL RESEARCH (2019)
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2018)
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
Xiaohong Ruby Xu et al.
BLOOD (2018)
Inhibitors of phosphodiesterase as cancer therapeutics
Ting Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Epstein–Barr Virus and Cancer
Paul J. Farrell
Annual Review of Pathology-Mechanisms of Disease (2018)
Sensitivity Analysis in Observational Research: Introducing the E-Value
Tyler J. VanderWeele et al.
ANNALS OF INTERNAL MEDICINE (2017)
Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies
Lauren R. Teras et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies
Ahmed E. Goda et al.
MOLECULAR ONCOLOGY (2015)
Epstein-Barr Virus Antibodies and the Risk of Associated Malignancies: Review of the Literature
Anna E. Coghill et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2014)
Dipyridamole intervention of breast cell carcinogenesis
Shambhunath Choudhary et al.
MOLECULAR CARCINOGENESIS (2014)
Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial
Michael Maeng et al.
LANCET (2014)
Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?
Pitchai Balakumar et al.
PHARMACOLOGICAL RESEARCH (2014)
Investigation of Epstein-Barr Virus as a Potential Cause of B-Cell Non-Hodgkin Lymphoma in a Prospective Cohort
Anneclaire J. De Roos et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer
Chunmei Wang et al.
CANCER PREVENTION RESEARCH (2013)
Dipyridamole prevents triple-negative breast-cancer progression
Daniela Spano et al.
CLINICAL & EXPERIMENTAL METASTASIS (2013)
Modulation of oxidative stress as an anticancer strategy
Chiara Gorrini et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Aspirin Resistance: Current Status and Role of Tailored Therapy
Jonathan Grinstein et al.
CLINICAL CARDIOLOGY (2012)
Landmark Analysis at the 25-Year Landmark Point
Urania Dafni
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2011)
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies
Richard J. Rickles et al.
BLOOD (2010)
A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma
Kimberly A. Bertrand et al.
BLOOD (2010)
Targeting cancer with phosphodiesterase inhibitors
Rajkumar Savai et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency
Bradley S. Dixon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dipyridamole, cerebrovascular disease, and the vasculature
Subrata Chakrabarti et al.
VASCULAR PHARMACOLOGY (2008)
Pro-posed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)
Lindsay M. Morton et al.
BLOOD (2007)
Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma
DE Rollison et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates
AS Weyrich et al.
CIRCULATION (2005)
Mechanisms of disease - Persistence of the Epstein-Barr virus and the origins of associated lymphomas
DA Thorley-Lawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
